Literature DB >> 17541959

The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.

R Heer1, C N Robson, B K Shenton, H Y Leung.   

Abstract

Abnormal differentiation in epithelial stem cells or their immediate proliferative progeny, the transiently amplifying population (TAP), may explain malignant pathogenesis in the human prostate. These models are of particular importance as differing sensitivities to androgen among epithelial cell subpopulations during differentiation are recognised and may account for progression to androgen independent prostate cancer. Androgens are crucial in driving terminal differentiation and their indirect effects via growth factors from adjacent androgen responsive stroma are becoming better characterised. However, direct effects of androgen on immature cells in the context of a prostate stem cell model have not been investigated in detail and are studied in this work. In alpha2beta1hi stem cell enriched basal cells, androgen analogue R1881 directly promoted differentiation by the induction of differentiation-specific markers CK18, androgen receptor (AR), PSA and PAP. Furthermore, treatment with androgen down-regulated alpha2beta1 integrin expression, which is implicated in the maintenance of the immature basal cell phenotype. The alpha2beta1hi cells were previously demonstrated to lack AR expression and the direct effects of androgen were confirmed by inhibition using the anti-androgen bicalutamide. AR protein expression in alpha2beta1hi cells became detectable when its degradation was repressed by the proteosomal inhibitor MG132. Stratifying the alpha2beta1hi cells into stem (CD133(+)) and transient amplifying population (TAP) (CD133(-)) subpopulations, AR mRNA expression was found to be restricted to the CD133(-) (TAP) cells. The presence of a functional AR in the TAP, an androgen independent subpopulation for survival, may have particular clinical significance in hormone resistant prostate cancer, where both the selection of immature cells and functioning AR regulated pathways are involved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541959     DOI: 10.1002/jcp.21154

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

1.  Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland.

Authors:  L Jiang; F Ivich; S Tahsin; M Tran; S B Frank; C K Miranti; Y Zohar
Journal:  Biomicrofluidics       Date:  2019-11-20       Impact factor: 2.800

2.  Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells.

Authors:  Bobby Bhatia; Ming Jiang; Mahipal Suraneni; Lubna Patrawala; Mark Badeaux; Robin Schneider-Broussard; Asha S Multani; Collene R Jeter; Tammy Calhoun-Davis; Limei Hu; Jianhua Hu; Spiridon Tsavachidis; Wei Zhang; Sandy Chang; Simon W Hayward; Dean G Tang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

3.  Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens.

Authors:  R Heer
Journal:  Ann R Coll Surg Engl       Date:  2011-09       Impact factor: 1.891

Review 4.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 5.  Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

6.  Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.

Authors:  Jing Tian; Soo Ok Lee; Liang Liang; Jie Luo; Chiung-Kuei Huang; Lei Li; Yuanjie Niu; Chawnshang Chang
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

Review 7.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

8.  New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

Authors:  Soo Ok Lee; Zhifang Ma; Chiuan-Ren Yeh; Jie Luo; Tzu-Hua Lin; Kuo-Pao Lai; Shinichi Yamashita; Liang Liang; Jing Tian; Lei Li; Qi Jiang; Chiung-Kuei Huang; Yuanjie Niu; Shuyuan Yeh; Chawnshang Chang
Journal:  J Mol Cell Biol       Date:  2012-07-24       Impact factor: 6.216

Review 9.  The many ways to make a luminal cell and a prostate cancer cell.

Authors:  Douglas W Strand; Andrew S Goldstein
Journal:  Endocr Relat Cancer       Date:  2015-08-25       Impact factor: 5.678

10.  Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor.

Authors:  Stuart C Williamson; Anastasia C Hepburn; Laura Wilson; Kelly Coffey; Claudia A Ryan-Munden; Deepali Pal; Hing Y Leung; Craig N Robson; Rakesh Heer
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.